(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
World’s tallest bridge and biggest museum named ‘greatest places of 2026’ - 2Are your hormones imbalanced? Doctors explain how to know if you need testing
- 3A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- 4Bahrain cracks down on dissent as war grinds on
- 5Find the Native Culinary Customs: Local Flavors
- How to Build a Yard That Helps Monarchs During Spring Migration
- Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- Inside Plan with Houseplants: An Aide
- Israel faces tough choices over haredi draft exemptions, legal expert warns
- 6 Shades Brands For Seniors
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- EU-funded BioSupPack project turns brewery waste into bioplastics
- OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
